{"id":391627,"date":"2014-06-11T00:00:00","date_gmt":"2014-06-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd3214-biopharma-non-small-cell-lung-cancer-previously-treated-egfr-wild-type-untested-decision-base-us-eu\/"},"modified":"2026-03-31T09:05:09","modified_gmt":"2026-03-31T09:05:09","slug":"dbaspd3214-biopharma-non-small-cell-lung-cancer-previously-treated-egfr-wild-type-untested-decision-base-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dbaspd3214-biopharma-non-small-cell-lung-cancer-previously-treated-egfr-wild-type-untested-decision-base-us-eu\/","title":{"rendered":"Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type\/Untested) | Decision Base | US\/EU | 2014"},"content":{"rendered":"<p><em>Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival?<\/em><\/p>\n<p>Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers; of these lung cancers, approximately 90% are <em>EGFR<\/em> wild-type\/untested. Despite significant advances in the treatment of advanced\/metastatic NSCLC in the first-line setting, treatment options for later-line settings have not changed over the past decade. Chemotherapies such as docetaxel (Sanofi\u2019s Taxotere, generics) and pemetrexed (Eli Lilly\u2019s Alimta) and the EGFR inhibitor erlotinib (Genentech\/Roche\/Chugai\/Astellas\u2019s Tarceva) remain the standards of care for <em>EGFR<\/em> wild-type\/untested patients. No targeted agents are available in the second- and later-line settings; therefore, these patients remain difficult to treat. Thus, significant clinical and commercial opportunity remains for novel, highly efficacious, and tolerable therapies.<\/p>\n","protected":false},"template":"","class_list":["post-391627","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-geography-us","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391627\/revisions"}],"predecessor-version":[{"id":394750,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391627\/revisions\/394750"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}